PTC Therapeutics (PTCT) Competitors $48.53 +0.39 (+0.81%) Closing price 04:00 PM EasternExtended Trading$48.54 +0.02 (+0.03%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIOShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris Ascendis Pharma A/S QIAGEN Blueprint Medicines BridgeBio Pharma PTC Therapeutics (NASDAQ:PTCT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment. Do institutionals & insiders hold more shares of PTCT or ITCI? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is PTCT or ITCI more profitable? PTC Therapeutics has a net margin of 33.56% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics33.56% -78.56% 32.11% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has more volatility & risk, PTCT or ITCI? PTC Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Do analysts rate PTCT or ITCI? PTC Therapeutics currently has a consensus target price of $65.00, suggesting a potential upside of 33.94%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media favor PTCT or ITCI? In the previous week, PTC Therapeutics had 10 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 11 mentions for PTC Therapeutics and 1 mentions for Intra-Cellular Therapies. PTC Therapeutics' average media sentiment score of 0.57 beat Intra-Cellular Therapies' score of 0.29 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, PTCT or ITCI? Intra-Cellular Therapies has lower revenue, but higher earnings than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M4.77-$363.30M$6.517.45Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 SummaryPTC Therapeutics beats Intra-Cellular Therapies on 12 of the 17 factors compared between the two stocks. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.85B$2.93B$5.50B$9.38BDividend YieldN/A2.46%4.25%4.06%P/E Ratio7.4520.3128.1019.86Price / Sales4.77183.28380.1579.14Price / CashN/A42.3835.5357.53Price / Book-3.417.838.265.72Net Income-$363.30M-$55.11M$3.24B$257.80M7 Day Performance-2.00%2.18%0.50%1.07%1 Month Performance-4.56%12.98%7.99%11.31%1 Year Performance41.94%1.98%28.68%17.01% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics4.4777 of 5 stars$48.53+0.8%$65.00+33.9%+40.9%$3.85B$806.78M7.451,410Analyst RevisionITCIIntra-Cellular Therapies0.9213 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9325 of 5 stars$20.52+1.1%$37.60+83.2%-19.0%$13.16B$3.12B11.662,682Analyst RevisionRDYDr. Reddy's Laboratories2.7945 of 5 stars$15.08flat$16.95+12.4%-6.7%$12.59B$3.81B22.8527,811News CoverageMRNAModerna4.2898 of 5 stars$29.90-1.9%$46.61+55.9%-74.4%$11.56B$3.24B-3.425,800Options VolumeAnalyst RevisionRGCRegencell Bioscience0.3346 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Positive NewsGap UpVTRSViatris3.1076 of 5 stars$9.20-1.3%$10.40+13.0%-20.2%$10.80B$14.74B-2.9032,000News CoveragePositive NewsASNDAscendis Pharma A/S3.7341 of 5 stars$175.98+1.0%$220.67+25.4%+24.6%$10.76B$393.54M-28.021,017Positive NewsQGENQIAGEN3.7289 of 5 stars$47.49-1.8%$49.40+4.0%+16.7%$10.56B$1.98B119.075,765Positive NewsBPMCBlueprint Medicines1.1224 of 5 stars$128.40+0.0%$128.06-0.3%+7.3%$8.29B$508.82M-51.98640Positive NewsBBIOBridgeBio Pharma4.6415 of 5 stars$43.50-1.1%$58.85+35.3%+61.0%$8.26B$221.90M-12.32400Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives RGC Alternatives VTRS Alternatives ASND Alternatives QGEN Alternatives BPMC Alternatives BBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTCT) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts